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Abstract
Alzheimer’s Disease (AD) is a degenerative neurologic disorder that is often defined
by beta-amyloid (Aβ) plaques. These Aβ plaques are formed from protein pieces that are
incorrectly cleaved from an amyloid precursor protein (APP). These protein segments,
cleaved from APP, are toxic due to increased “stickiness”. They cling together to create
protofibrils that eventually mature into neuronal plaques. Aβ plaques lead to neuronal cell
death causing classic AD symptoms: memory loss, a decline in speech and motor control,
and personality changes. One connection between high Aβ plaques levels and AD is chronic
sleep loss or disruption. Night shift workers, even if they make up the same hours of sleep
after a shift, disrupt their circadian rhythms and alter their sleep-wake cycle. Disruption of
sleep leads to Aβ plaque build-up. One suggested function of REM sleep is to “flush” toxins,
including these Aβ plaques. Without quality REM sleep, Aβ plaques build in the brain. By
using a radiotracer, neuronal plaque level can be measured and the results compared to the
varying types of night shift work. Thus, the crucial role that sleep plays in brain health may
explain the underlying causes of AD.

Introduction
Alzheimer’s Disease Background:
Alzheimer's Disease (AD) is a devastating disease often associated with and
described as a progressive neurodegenerative disorder resulting in memory loss, reduction in
cognitive function, and confusion (Kumar and Tsao, 2019). It is shockingly common and is
the sixth leading cause of death in the United States and is often evaluated based on the
Global Deterioration Scale - “GDS” (Kumar and Tsao, 2019). The GDS is a way to classify
patients based on observed clinical characteristics related to AD. Stages 1-3 indicate predementia stages while stages 4-7 are associated with dementia. The most notable symptom of
AD is memory loss. Often the first few signs of AD are the inability to do small tasks
successfully that are usually performed every day. These tasks include: remembering
directions to work, being unable to make a meal that has been made several times before, or
misplacing personal items, such as car keys in the refrigerator (Kumar and Tsao, 2019).
Additional symptoms include issues with speech, mood or personality changes, as well as
decreased motor control.

AD is a disease of synaptic failure, which is defined as the diminishing of crucial
connections between different parts of the brain, in which the ability for neurons to synapse
correctly becomes reduced, decreasing the overall function of the brain. The synapse
reduction starts in the hippocampus which is the portion of the brain that primarily deals with
memory (Kumar and Tsao, 2019). This would explain why memory loss is one of the first
signs of AD. This decreased function is directly correlated with decreased brain mass
because as the connections in the hippocampus fail, and neuronal death occurs, these parts of
the brain atrophy (Pini et al., 2016). The causes of this synaptic failure in the brain are not
fully understood, but some potential causes are: alterations in the blood-brain barrier,
decrease in function of metabolic processes, oxidative stress, and brain atrophy caused by Aβ
plaques and tau tangles. This last reason has the most support from researchers relating brain
changes and AD symptoms (O’Brien and Wong, 2011).

Plaques Background:
The main focus of this paper is the beta-amyloid (Aβ) plaques that are the signature
marker of AD (O’Brien and Wong, 2011). The Aβ plaques are formed from sticky Aβ
proteins that are cleaved from the amyloid precursor protein (APP). APP is a single-pass
transmembrane protein found most densely concentrated in the synapses of neurons (O’Brien
and Wong, 2011). The exact function of APP is still unknown. APP in non-AD individuals is
cleaved by a non-amyloidogenic process. First, alpha secretase cleaves APP, then, gamma
secretase cuts APP, forming a nontoxic beta-amyloid protein. These non-amyloidogenic
cleaved portions of APP are thought to help neurons function (Jann, 2010). In contrast, in
AD patients, APP is cleaved through an amyloidogenic process. This happens when beta
secretase first cuts the APP, followed by cleavage by gamma secretase to form the Aβ protein

(See Figure 1). After the Aβ protein are cleaved from the APP, they form monomers which
come together to form oligomers. The oligomers are soluble and, therefore, can spread
throughout the brain. The oligomers then convert into protofibrils through a structural
change. This change takes the leftover loose Aβ peptide strands and rapidly converts them
into α-helical and parallel β-sheet structures. These newly made protofibrils are now
insoluble (Chen et al., 2017). These protofibrils are the precursors to the mature fibrils that
are the basis of the plaque formation in neurons. In comparison to the non-amyloidogenic
cleaved peptides of APP, which are soluble and non-sticky, these fibrils that undergo the
amyloidogenic process are insoluble and sticky. Due to this abnormality, these
amyloidogenic Aβ fibrils cling together to form toxic plaques that disable neuron function
(Chen et al., 2017). These plaques appear to underlie many of the classic symptoms seen in
AD, such as; memory loss, disorientation, mood changes, and motor skill degradation
(Kumar and Tsao, 2019).

Figure 1: Amyloid precursor protein (APP) cleaving processes in Alzheimer’s Disease (AD)
cells and in non-AD cells. The left side, in blue, represents the non-amyloidogenic process
creating non-toxic and non-sticky Aβ protein pieces. The right side, in pink, represents the
mutated amyloidogenic process that typically occurs in AD patients. Reproduced figure from
Patterson et al., 2008.

Although there is extensive research about APP and the different cleaving processes,
there is some controversy in how these plaques directly relate to AD symptoms. Although
these Aβ plaques initially form in the hippocampus, the progression of their production and
dispersion throughout the brain does not necessarily correspond to the symptom
advancement that is classically seen in AD. One explanation for this could be the
simultaneous creation of tau tangles in the brain. Tau tangles are created from the tau protein,
which helps to stabilize microtubules in the axons of neurons. Normally, neuronal axons are
entirely lined with this tau protein that holds together and stabilizes the microtubules that
make up the neuron. In Alzheimer’s, tau is mutated so that it destabilizes, prompting the
axon, and, eventually, the entire neuron to degenerate. The axonal tau pieces fall off the
neuronal microtubules and combine to form tangles inside the neuron (Jann, 2010). This, in
turn, disables the neuron transport system. The neuron transport system is the pathway that
neurons use to synapse and communicate with each other. When these portions of the brain
die, it causes brain regions to disconnect from each other. These tangles usually originate in
the hippocampus, causing tissue shrinkage. This causes the most common and devastating
symptom: memory loss (Jann, 2010). The exact mechanism of the relationship between
pathology and symptoms is not known, but the current theory is that they work in tandem to
cause the classic symptoms we see in AD.

Connection with Sleep:
Recently, increased Alzheimer’s Disease (AD) risk has been connected to a variety of
lifestyle factors. People with poor quality of sleep are more likely to have Alzheimer’s
compared to those that have quality sleep throughout a lifetime (Brown et al., 2016). As
defined by the National Sleep Foundation, shift work is “work that takes place on a schedule

outside the traditional 9 am - 5 pm day. It can involve evening or night shifts, early morning
shifts, and rotating shifts” (National Sleep Foundation, 2019). Being a night shift worker
means that you get fewer hours of sleep than the rest of the population, therefore not as many
REM cycles and not as deep or good quality of sleep (Nabe-Nielsen et al., 2019). One of the
most researched theories has been the connection between AD risk with a lack of sleep
throughout a lifetime. This bidirectional relationship indicates that the connection between
sleep and AD moves both ways because with AD patients, we see a decline in number of
sleep hours and an increase in wakefulness during the night time hours (Minakawa et al.,
2019). Similarly, people who have had lifetime sleep issues, such as insomnia or sleep apnea,
have an increased risk of having AD later in life (Ju et al., 2016).
The main question now is: why? Sleep, specifically rapid eye movement or REM
sleep, is believed to help remove the beta-amyloid plaques in the brain (Brown et al.,
2016). Studies have shown that 24 hours without sleep significantly raises levels of Aβ
plaques in the hippocampus of the human brain (Shokri-Kojori et al., 2018). Based on this
research, theoretically, one demographic that would be particularly at risk for AD would be
people who work night shifts. A common misconception with people who work night shifts
is that they just ‘become nocturnal.’ Night shifts require people to completely alter their
sleep-wake cycle by sleep depriving themselves for the shifts. Nocturnal animals, their sleepwake cycles, and their circadian rhythms are created for the “night shift.” In contrast, the
human body cycles are not meant for these hours. For the select few who do work night
shifts, it is common to sleep during the day, thereby further altering the natural circadian
rhythm of the body. It is inevitable that when working night shifts, the body will lose sleep
and be altered in some way for at least 24 hours after the shift.

Overall Hypothesis:
For the proposed experiment, it is hypothesized that people who participate in a
significant amount of night shift work will have higher levels of Aβ plaque buildup in the
hippocampus and therefore have an increased risk of developing AD.

Predictions:
For the Control group getting a regular 6-8 hours of sleep out of 24 hours during a
natural daytime sleep-wake cycle, we would expect a significantly lower level of Aβ plaque
at both six and twelve months. For the first group, night shift type 1 (NST1), working 4-6
night shifts a month and not getting a regular 6-8 hours of sleep out of 24 hours during a
natural daytime sleep-wake cycle, we would expect to see a slightly higher than average
amount of Aβ plaque level than the Control group at both six and twelve months. For the
second group, night shift type 2 (NST2), they will be working 12-18 night shifts a month and
not getting a regular 6-8 hours of sleep out of 24 hours during a natural daytime sleep-wake
cycle. We would expect a significantly higher level of Aβ plaque at both six and twelve
months. For the last group, night shift type 3 (NST3), they will be working 18+ night shifts
per month and not getting a regular 6-8 hours of sleep out of 24 hours during a natural
daytime sleep-wake cycle; they will do this for six months. After working night shifts for six
months, the group will switch and discontinue all night shift work. For the last six months of
the experiment, the NST3 group will stop working all night shifts and will be getting a
regular 6-8 hours of sleep out of 24 hours during a natural daytime sleep-wake cycle. Here,
for NST3 at six months, we would expect similar results to the NST2 group, therefore, we
would see a significantly higher level of Aβ. For months seven-twelve, we would expect the
NST3 group to start to mimic the Control group, having a lowered level of Aβ plaque at the

twelve-month measurement. For NST3, it is hypothesized that the results will not be
significantly different from the Control group for the third measurement at month twelve.
To control for stress levels during night shifts, cortisol measurements were taken as a
control variable. It has been shown that cortisol levels tend to be elevated after a night of
sleep loss (Leproult et al.,1997). Therefore, it is hypothesized that cortisol levels would be
elevated per amount of sleep lost. Therefore, for NST1, cortisol levels would be slightly
elevated throughout the experiment, whereas for NST2, cortisol levels would be elevated in
comparison to the control group. For NST3, it is hypothesized that cortisol levels would be
elevated for the six months when working night shifts. But, after not working night shifts for
six months, we would see a near normal cortisol level measurement at month 12.
Additionally, it is hypothesized that the control group will have normal cortisol levels
throughout the entirety of the experiment as they are having no sleep pattern changes.

Proposed Materials and Methods
Subjects:
Each subject was given a questionnaire prior to joining the study. This questionnaire
inquired about previous sleep habits and jobs, as well as household life. See Supplemental
Information #1 for more details. Control group (n

control

=50), NST1 (n =50), NST2 (n =50),
NST1

NST2

and NST3 (n =50) were nurses (n =200) working across three teaching hospitals in one
NST3

total

county. Each participant will take a Mini-Mental State Exam (MMSE) at the start of the
experiment to ensure a non-abnormal score (between 25-30). See Supplemental Information
#2 for more details. See Table 1 for more information per group.

Mean
Age
(years)

MMSE
Score
(average
score)

Mean Total
Night Shifts
Worked at
Baseline

Mean Total Night
Shifts Worked
After 6 Months
per Participant

Mean Total Night
Shifts Worked
After 12 Months
per Participant

Control 29

29

0

0

0

NST1

30

30

0

24

48

NST2

28

30

0

90

180

NST3

29

29

0

100

100

Table 1. Evaluation of specific characteristics of each group (Control, NST1, NST2, NST3).
These include mean age (years), mean MMSE score (average MMSE score), and mean
number of total night shifts worked at baseline, six, and twelve months for each participant.

Setup:
There were four groups in this experiment (Control, NST1, NST2, NST3). All
participants were under the age of 35 and were in their first year of working night shift
rotations. The Control group was a group of nurses that had never worked night shifts and
therefore slept, at minimum, seven to nine hours a night for one year. NST1 involved nurses
who work four-night shifts a month for one year (one night shift a week), therefore getting
fewer than five hours of sleep at least four times in every 30 days. NST2 consisted of nurses
that work 12 - 18 night shifts a month for one year (3-5 night shifts a week), therefore getting
fewer than 5 hours of sleep at least ten times in every 30 days. NST3 comprised of nurses
who work 18+ night shifts for 3-6 months and then return to a regular sleep schedule (7+
hours a night) for the remainder of the experimental year.

Measuring AB Plaques:
To measure the Aβ plaques in the brain, a radiotracer called Pittsburgh Compound B
(PiB) was used. PiB is one of the most widely used ligands for tracing Aβ plaques in living
human subjects as it is one of the more accurate tracers (Rowe et al., 2008). In mice testing

trials, PiB was found to have a rapid response in the brain, as well as, to clear out quickly
after. In addition, it has been found that PiB has no toxic side effects (Klunk et al., 2004).
These results are the reasons why PiB was used for this experiment (Klunk et al., 2004). PiB
binds to both Aβ40 and Aβ42 plaques, but for the purpose of this experiment, only Aβ42 was
measured. Aβ42 has been found to be the most insoluble and sticky form of Aβ, therefore the
most harmful plaque and the one that would cause the most neuronal damage. For this
reason, it will be the only form that will be measured throughout the proposed experiment.
The amount of PiB retention in a brain region is equivalent to the amount of Aβ plaques in
that portion of the brain (Klunk et al., 2004). PiB was intravenously injected with a similar
concentration to what has been used in previous other studies (Klunk et al., 2004). Positron
Emission Tomography, or a PET Scan, was used to visualize the PiB retention throughout the
brain. The resolution was similar to what has been used in previous other studies (Klunk et
al., 2004). Although the entire brain was imaged, the main focus was in the hippocampus.
Each of the four groups would have PiB levels would be measured one month, six
months, and 12 months after the start of the experiment can compared to baseline levels at
the start of the study: the first, six, and twelfth month of the proposed experiment.

Measuring Cortisol Levels:
In addition to measuring plaque accumulation, cortisol levels in the blood were tested
to compare the amount of sleep with stress levels. If cortisol levels change during the course
of the experiment, then other parts of the brain may also be affected. Cortisol levels were
measured directly before, and then after, a night shift. The first measurement took place
during the initial portion of the study during one of the first night shifts during the first month
of the study. The second measurement was at the six-month marker and was within 24 hours

after a night shift. The last measurement was in the twelfth and last month of the measured
year. This was also after a night shift. The measurement consisted of a saliva test that was
then analyzed in order to look at cortisol levels.

Phone Application:
In order to help participants keep track of their sleep-wake cycle, each participant
used a smart phone application. This helped eliminate participant memory bias because each
person had the ability to record real-time information. This gave the study the best and most
up to date information possible therefore eliminating as much variation or bias. This
eliminated participants’ having to recall or estimate how many hours they worked weeks or
months later.
Participants recorded information about each work shift, for both regular day or night
shifts. For work times, they recorded the hours worked per shift, the perceived stress level
per shift, and their perceived general well-being before and after each shift. Perceived stress
level per shift will be measured on a twenty-point scale, from 1 being relaxed and not
stressed to 20 being most stress ever felt. The app works so that the participants input their
monthly shift schedule into their phone application. From that, the app reminded them before
their shift to fill out the “pre-shift” survey. Then, about 8-10 hours later, the “post-shift”
survey was made available. Participants were also asked to record their nightly sleep hours
and perceived sleep quality.

Proposed Results
Cortisol levels were measured before the experiment began, at month six, and month
twelve. The measurements were taken within the 24 hours after a recent work shift. The
cortisol level averages for the control, NST1, NST2, and NST3 groups were 3.98, 4.62, 4.58,

and 5.03, respectively. For the baseline measurements there was no difference among the
four groups as no participants had worked a night shift and therefore the body’s stress and
cortisol levels were relatively low. The six-month measurements of the average cortisol
levels for the control, NST1, NST2, and NST3 groups, were 4.88, 11.62, 17.39, and 20.27,
respectively. At the six-month measurement, it was seen that the more average total night
shifts worked per person directly correlated with a higher cortisol level (Table 1, Figure 2).
This was found to be true again, during the twelve-month measurement, where the mean
cortisol levels for the control, NST1, NST2, and NST3, groups were 5.82, 16.88, 20.61, and
11.62 respectively (Figure 2).
For the Aβ42 plaque measurement, each of the four groups were measured three
times: at baseline, six months, and twelve months. During each measurement period, there
were three time measurements taken at 10, 20, and 30 minutes’ post radiotracer injection.
Because PiB actively binds to Aβ42 plaques, it can be assumed that the more PiB in the brain
over time is indicating a higher Aβ42 plaques level. The higher the amount of PiB retention,
the larger the amount of Aβ42 plaques in the brain. The baseline measurements were nearly
all identical, as none of the participants had worked any night shifts yet. Throughout the
experiment, the control group stayed relatively the same, with little to no sleep loss almost no
Aβ42 plaque accumulation throughout the brain. Once the NST1, NST2, and NST3 groups
began working night shifts, there was a steady spike in PiB retention. For NST1 at six
months, there was some Aβ42 plaque accumulation in the brain, but it returned to a relatively
normal level (Figure 4b). For NST2 at six months, the participants on average worked 90
night shifts (Table 1). PiB retention levels and the Aβ42 plaque accumulations were
significantly higher than the control group. For NST3, there was the highest level of Aβ42

plaque build up, as well as the longest and largest PiB retention, because at six months this
group had worked the highest number of night shifts compared to all other groups (Table 1,
Figure 4b). This showed that the participants were working a significant amount of night
shifts during the first half (six months) of the experiment, and therefore had some Aβ42
plaque accumulation. However, as the experiment went on, and they stopped working night
shifts for the second half of the experiment, the PiB retention time recovered back to baseline
levels at the twelve-month measurement for the NST3 group (Figure 4c). In contrast, in the
NST1 and NST2 groups there was an increasingly higher level of PiB retention as they
continued to work the most night shifts in comparison to the control and NST3 groups
(Figure 4c).
a)

b)

c)

Figure 2: Mean cortisol levels measured at each interval of the proposed experiment for
Control, NST1, NST2, and NST3 groups. Plasma cortisol levels were recorded from a blood
draw from each participant, and then a mean from each group was taken (units: μg/dL). Error
bars represent 95% +/- confidence interval. a) Baseline cortisol measurement during the first
month of the proposed experiment. b) Halfway cortisol measurement during the sixth month
of the proposed experiment. c) End cortisol measurement during the last (twelfth) month of
the proposed experiment.

Figure 3: PET scan of the brain with PiB standardized uptake value3 (in green) in a healthy
control subject’s brain (Left) in comparison to a subject after six months of prolonged sleepwake cycle disruption (Right). Reproduced figure from (Leyton et al., 2011).
a)

b)

c)

Figure 4: Mean of reported standardized uptake value (SUV ) of PiB in the right
hippocampus. The SUV correlates to the amount of Aβ42 plaques being bound in the brain.
The more SUV measurements after 30 minutes post-PiB injection, the more Aβ42 plaques in
the brain. a) Baseline SUV measurement before any worked night shifts. b) Halfway SUV
measurement during the sixth month of the proposed experiment. c) End SUV measurement
during the twelfth month of the proposed experiment.
R

R

R

R

R

Discussion
The data has shown that there is a strong correlation between chronic sleep
deprivation and an increase in Aβ42 plaques in the brain, in particular, in the hippocampus.
Because we know that the sticky Aβ42 plaques are a large factor in causing AD, it can be
seen that sleep disturbance due to night shift work, over a prolonged period of time, can lead
to an increased risk of AD (Shokri-Kojori et al., 2018). In order to observe the effects of
sleep alteration on the brain, a radiotracer, PiB, as well as a PET scan, were used. PiB binds
to the sticky plaque material of Aβ42, therefore, the higher the levels of Aβ42 in the brain,
the longer PiB will be retained in the brain because it has more material to bind. This peak in
Aβ42 plaque levels was seen to be most prevalent in NST2 at both six and twelve months, as
well, as NST3 at six months. Because the PiB retention time recovered back to baseline
levels, it can be seen that the brain is able to clear out the Aβ42 plaque accumulations after a
prolonged period of quality sleep recovery (Figure 4c).
For cortisol measurements, there was a significant increase seen in the data for groups
working the most amount of night shifts. The NST1 and NST2 groups had the highest
cortisol measurements at 12 months. The control groups cortisol measurements were
relatively stable and normal throughout the experiment. In contrast, the NST3 group was had
the highest measure of cortisol at six months because they had worked the highest number of
night shifts. But, after a six-month recovery period, the NST3 cortisol levels decreased
significantly, although not entirely back to baseline. These results show that even with a
prolonged amount of sleep recovery after working a large total number of night shifts,
cortisol levels are not able to entirely return to normal. These results prove that prolonged
night shift work, even with a significant recovery period, does act detrimentally on the body.

Limitations and Follow Up Studies:
One potential limitation for this study could be the fact that that PiB has a short halflife. A short half-life has been suggested to make the imaging of the PET scan more difficult
because it clears out of the brain faster (Rowe et al., 2008). This is one reason that several
studies looking into the connection between sleep deprivation and AD have chosen other
radiotracers, such as 18F-florbetaben (Shokri-Kojori et al., 2018). Another, more novel,
radiotracer is 18F-BAY94-9172, which is a combination of 18F-florbetaben and PiB, which
has also been used in some studies (Rowe et al., 2008). Although having a short half-life has
downsides, it has some positives because it is less invasive and clears out of the brain faster,
making the analyzing process much quicker for both researchers and participants.
Additionally, another potential limitation for this study could be the fact that a lot of
the information is self-reported. The questionnaire, as well as all the information reported in
the phone application, is self-reported. Although participants would be asked to be truthful, it
would be understandable to see some bias in terms of reporting an incorrect number of
sleeping hours, which could potentially skew the researchers’ understanding of each
participant’s sleep-wake cycle. One way to correct this would be to do a minimized version
of the study in the lab. For example, having participants be sleep deprived while being
observed in the lab and then having their Aβ42 plaque accumulation levels measured could
be a way to significantly control for that sort of bias.

Conclusion
This proposed study attempts to correlate sleep loss and circadian rhythm disruption
with an increased risk for Alzheimer’s Disease. The link between these two is the presence of
beta-amyloid plaques. These mutated protein segments become toxic and sticky, unlike their

non-mutated counterparts, and eventually create plaques. The clinging nature of these
plaques causes disruption of neuronal connections, often causing memory loss, the hallmark
symptom of Alzheimer’s Disease (Kumar and Tsao, 2019). As lots of previous background
research has suggested, losing even one night of sleep can cause significant Aβ42 plaque
accumulation in the brain, and, more specifically, in the hippocampus (Shokri-Kojori et al.,
2018). After tracking participants on varying work and night shift schedules, it can be seen
that there was a significant increase in Aβ42 plaque accumulation over a prolonged period of
disturbing the sleep-wake cycle. These results implicate that shift work is unhealthy and that
the way night shifts are assigned needs to be changed. If a different system could be put in
place to allow for adequate recovery, the overall risk of AD could potentially decrease.
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Supplemental Information
Supplemental Information #1: Sleep Study Questionnaire
Name: _____________________________

Date of birth: ______________
Address:
_____________________________________________________________________
Phone: ____________________
E-mail address: __________________________
In case of emergency, whom may we contact?
Name: ______________________________________
Relationship: _____________________________________
Phone: ________________________________________
Personal physician
Name: __________________________________
Phone: ____________________ Fax: ____________________

Present/Past History
Have you had OR do you presently have any of the following conditions? (Check if
yes.)
____ Recent operation
___ High blood pressure
___ Seizures
___ Diabetes
___ High cholesterol
___ Chest pains
___ Palpitations or tachycardia (unusually strong or rapid heartbeat)
___ Intermittent claudication (calf cramping)
___ Pain, discomfort in the chest, neck, jaw, arms, or other areas with or
without physical exertion
___ Insomnia
___ Sleep Apnea
___ Other:

Family History
Have any of your first-degree relatives (parent, sibling, or child) experienced the
following conditions? (Check if yes.) In addition, please identify at what age the
condition occurred.
___ Alzheimer’s Disease
___ Dementia
___ Parkinson’s Disease
___ Heart attack
___ Heart operation
___ Congenital heart disease
___ Premature death before age 50
___ Significant disability secondary to a heart condition

___ Marfan syndrome
___ High blood pressure
___ High cholesterol
___ Diabetes
___ Other major illness:

Explain checked items:

Activity History
How were you referred to this program? (Please be specific.)
Date of your last physical examination performed by a physician:
Do you have, or have you ever had, issues sleeping, either too much or not enough?
Yes ___ No ___ If yes, briefly describe:
Do you have injuries (bone or muscle disabilities) that may interfere with exercising?
Yes ___ No ___ If yes, briefly describe:
Do you smoke? Yes ___ No ___ If yes, how much per day and what was your age
when you started? Amount per day ______ Age ______
List the medications you are presently taking.

From NSCA, 2012, NSCA’s essentials of personal training, 2nd ed., J. Coburn and M. Malek (eds.), (Champaign, IL:
Human Kinetics).

Supplemental Information #2: Mini Mental State Exam
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